Safety Assessment of T4090 Eye Drops in Ocular Hypertensive or Glaucomatous Patients.

Last updated: February 6, 2024
Sponsor: Laboratoires Thea
Overall Status: Active - Not Recruiting

Phase

1/2

Condition

Ocular Hypertension

Glaucoma

Treatment

Placebo

Kinezodianone R hydrochloride

Clinical Study ID

NCT05389267
LT4090-101
  • Ages > 18
  • All Genders

Study Summary

The study purpose is to evaluate the safety of T4090.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Informed consent dated and signed.
  • Both eyes diagnosed open-angle glaucoma or ocular hypertension

Exclusion

Exclusion Criteria:

  • History of trauma, infection, clinically significant inflammation within the previous 6 months
  • Known or suspected hypersensitivity to one of the components of the InvestigationalMedicinal Product(s)
  • Pregnancy or breast-feeding

Study Design

Total Participants: 120
Treatment Group(s): 2
Primary Treatment: Placebo
Phase: 1/2
Study Start date:
July 05, 2022
Estimated Completion Date:
December 31, 2024

Connect with a study center

  • Dr EL-HARAZI

    Glendale, California 91204
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.